Getein Biotech

Getein Biotech Debt

The Debt of Getein Biotech (603387.SS) as of Oct 16, 2026 is 577.19 M CNY. In the previous year, Debt was 644.00 M CNY — a change of -10.37% (lower).

Debt

577.19 MCNY

YoY

-10.37%

Last updated:

In 2024, Getein Biotech's total debt was 577.19 M CNY, a -10.37% change from the 644.00 M CNY total debt recorded in the previous year.

The Getein Biotech Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
31.24 M CNY
Jan 1, 2019
95.00 M CNY
Jan 1, 2020
384.79 M CNY
Jan 1, 2021
496.47 M CNY
Jan 1, 2022
591.02 M CNY
Jan 1, 2023
644.00 M CNY
Jan 1, 2024
577.19 M CNY
The Getein Biotech Debt history
YEARDebtYoY
577.19 MCNY-10.37%
644.00 MCNY+8.96%
591.02 MCNY+19.05%
496.47 MCNY+29.02%
384.79 MCNY+305.04%
95.00 MCNY+204.12%
31.24 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Getein Biotech Stock analysis

What does Getein Biotech do? Getein Biotech Inc, listed on the Shanghai Stock Exchange under ticker 603387.SS, is a biotechnology company headquartered in Nanjing, China. The company went public on July 17, 2017, and currently employs 2,508 full-time staff. Its primary business focuses on the medical health industry chain, with operations centered around in vitro diagnostic reagents and related instruments. The company produces a range of diagnostic reagents, including Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, and hemagglutination reagents. It also develops diagnostic instruments such as the immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000, and the five classification blood cell analyzer BHA-5000. In addition to manufacturing, Getein Biotech offers testing and agency services. Its products are distributed both domestically within China and internationally. The company maintains a website at www.getein.com.cn for further information. As a biotechnology firm operating in the healthcare sector, Getein Biotech Inc is positioned within the broader health care industry, contributing to diagnostic solutions for medical professionals and institutions. The company's focus on in vitro diagnostics aligns with its role in supporting healthcare systems through advanced testing technologies and equipment. Getein Biotech is one of the most popular companies on Eulerpool.

Debt Details

Understanding Getein Biotech's Debt Structure

Getein Biotech's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Getein Biotech's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Getein Biotech’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Getein Biotech’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Getein Biotech stock

Debt of Getein Biotech is 577.19 M CNY in 2024.

Debt of Getein Biotech changed from 644.00 M CNY to 577.19 M CNY, representing a -10.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Getein Biotech since 2006 – with annual values, charts, and detailed analysis.

Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Getein Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Getein Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Getein Biotech